Bristol Myers pays $100M for a different kind of ADC
网页2023年11月6日 · Under the terms of the deal, Bristol Myers will pay Orum $100 million for the program and commit to paying as much as $80 million more if certain milestones are met. Orum describes its therapy, dubbed ORM-6151, as an antibody-enabled protein degrader, merging the concept of an antibody-drug conjugate with the field of protein …
Eli Lilly adds ALS drug prospect with QurAlis deal
网页2024年6月3日 · QurAlis, a Cambridge, Massachusetts-based biotechnology company developing drugs for neurodegenerative diseases, on Monday announced it has licensed an experimental medicine for ALS and frontotemporal dementia to Eli Lilly. Lilly will pay the startup $45 million upfront for rights to a therapy called QRL-204 and currently in …
Drug deals, launches in focus as pharma earnings begin
网页2022年7月18日 · A $40 billion cancer drug deal? Pharma dealmaking has picked up as the value of many biotechnology companies remains depressed following a monthslong market downturn. Since April, there have been four buyouts worth greater than $1 billion, including Pfizer’s $11.6 billion acquisition of Biohaven Pharmaceuticals.
Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary
网页2023年10月23日 · Through the deal, Roche will acquire the subsidiary, called Telavant, and gain rights to the drug in the U.S. and Japan. The Swiss pharmaceutical company is also promising a “near-term” milestone of $150 million. Code-named RVT-3101, Roivant’s treatment is being studied for inflammatory bowel disease, a common gut ailment that …
Boehringer adds to cancer drug pipeline with deal for startup Nerio
网页2024年7月29日 · Boehringer Ingelheim is investing again in immuno-oncology, announcing Monday a deal to acquire the San Diego-based biotechnology startup Nerio Therapeutics and its slate of preclinical drug candidates. Worth up to $1.3 billion, the acquisition hands Boehringer access to a research program the German pharmaceutical company …
Biogen, Ionis shelve ALS drug following study failure
网页2024年5月16日 · Biogen and Ionis Pharmaceuticals are stopping development of an experimental drug for ALS following new clinical trial results that didn’t meet the companies’ expectations. The trial, which enrolled almost 100 people with the nerve-destroying disorder, found the drug actually worked as intended. Biogen and Ionis had designed it to lower ...
Bayer names former Roche executive Bill Anderson as new CEO
网页2023年2月8日 · Sean Gallup via Getty Images. German drugmaker Bayer on Wednesday named veteran pharmaceutical executive Bill Anderson to replace current head Werner Baumann as its next CEO, shaking up the company’s leadership as it tries to fend off activist investors. Anderson, who stepped down as the head of Roche’s pharma division late last …
Merck to buy eye drug developer for $1.3B - BioPharma Dive
网页2024年5月29日 · Merck & Co. on Wednesday said it has agreed to buy privately held eye drug developer EyeBio for $1.3 billion in cash upfront and as much as $1.7 billion in future milestone payments. Backed by SV Health Investors, Samsara BioCapital and Jeito Capital, EyeBio focuses on developing treatments for vision loss associated with retinal vascular ...
FDA clears Gilead drug acquired in $4.3B buyout - BioPharma Dive
网页2024年8月15日 · For the latter group of patients, the regulatory clearance specifies combination use of Livdelzi and ursodeoxycholic acid, Gilead said Wednesday. Livdelzi’s approval comes just a few months after Gilead spent $4.3 billion to buy CymaBay Therapeutics, the company that developed the drug, then known as seladelpar.
FDA approves Ascendis drug for rare endocrine condition
网页2024年8月12日 · Dive Brief: The Food and Drug Administration on Monday approved a hormonal replacement drug from Ascendis Pharma for a rare endocrine condition known as hypoparathyroidism. The drug, which Ascendis will sell as Yorvipath, is a prodrug formulation of the parathyroid hormone, levels of which are insufficiently low in the …